Buy or sell Mammoth Biosciences stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Mammoth Biosciences Stock

CRISPR-Based Disease Detection Platform



Notable Investors

Mayfield Fund


San Francisco CA, US

Total Funding


About Mammoth Biosciences Stock

Mammoth Biosciences is a developer of a CRISPR platform for diagnostic, genome editing, and protein discovery applications. Mammoth's Diagnostic services allows customers to detect molecules that may be indicative of a particular disease. Genome editing services allows customers to edit DNA sequences. Mammoth's protein discovery segment aims to expand CRISPR applications by detecting new proteins that fit CRISPR requirements.

Mammoth Biosciences was founded in 2017 and based in San Francisco, California.


Funding History

July 2018$18.1M
January 2020$36.8M
January 2020$7.4M
May 2020$44.4M
May 2020$748K
July 2021$100M
July 2021$50.0M


Chief Executive Officer

Trevor Martin

Chief Technology Officer

Janice Chen

Chief Science Officer

Lucas Harrington


Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Mammoth Biosciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 260K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: